环磷酰胺联合熊去氧胆酸治疗原发性硬化性胆管炎疗效观察  

Efficacy Observation of Cyclophosphamide Combined with Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis

作　　者：吉鹏飞[1] 杨红燕[1] JI Pengfei;YANG Hongyan(Baotou Central Hospital,Baotou,Inner Mongolia,China 014040)

机构地区：[1]内蒙古自治区包头市中心医院,内蒙古包头014040

出　　处：《中国药业》2023年第S01期50-52,共3页China Pharmaceuticals

摘　　要：目的探讨环磷酰胺联合熊去氧胆酸治疗原发性硬化性胆管炎的临床疗效。方法选取医院2020年5月至2022年3月收治的原发性硬化性胆管炎患者64例,按随机数字表法分为观察组和对照组,各32例。对照组患者使用熊去氧胆酸进行常规治疗,观察组在对照组治疗基础上加用环磷酰胺,均治疗4周。结果与对照组比较,观察组各项生活质量评分明显升高(P<0.05),各项血清胆红素指标均明显更低(P<0.05)。观察组总有效率为96.88%,显著高于对照组的81.25%(P<0.05)。观察组和对照组不良反应发生率相当(9.38%比12.50%,P>0.05)。结论环磷酰胺联合熊去氧胆酸治疗原发性硬化性胆管炎疗效好,可有效改善各项临床指标,提高患者生活质量,且安全性良好,值得临床推广。Objective To investigate the clinical efficacy of cyclophosphamide Combined with Ursodeoxycholic Acid in the treatment of primary sclerosing cholangitis.Methods A total of 64 patients with primary sclerosing cholangitis admitted to the hospital from May 2020 to March 2022 were selected and divided into the observation group and the control group by random number table method,with 32 patients in each group.The patients in the control group received routine treatment with ursodeoxycholic acid,on this basis,the patients in the observation group received cyclophosphamide.Both groups were treated for four weeks.Results Compared with those in the control group,the score of various quality of life in observation group was significantly higher(P<0.05),serum bilirubin indicators were significantly lower(P<0.05).The total effective rate in the observation group was 96.88%,which was significantly higher than 81.25%in the control group(P<0.05).The incidence of adverse reactions was similar between the observation group and the control group(9.38%vs.12.50%,P>0.05).Conclusion Cyclophosphamide in the treatment of primary sclerosing cholangitis is effective and safe,which can improve various clinical indicators and quality of life,and it is worthy of clinical promotion.

关 键 词：原发性硬化性胆管炎 环磷酰胺 临床疗效 不良反应 

分 类 号：R969.4[医药卫生—药理学] R975[医药卫生—药学]